Literature DB >> 17709422

Nucleotide-binding oligomerization domain protein 2-deficient mice control infection with Mycobacterium tuberculosis.

Sheetal Gandotra1, Sihyug Jang, Peter J Murray, Padmini Salgame, Sabine Ehrt.   

Abstract

Nucleotide-binding oligomerization domain proteins (NODs) are modular cytoplasmic proteins implicated in the recognition of peptidoglycan-derived molecules. NOD2 has recently been shown to be important for host cell cytokine responses to Mycobacterium tuberculosis, to synergize with Toll-like receptor 2 (TLR2) in mediating these responses, and thus to serve as a nonredundant recognition receptor for M. tuberculosis. Here, we demonstrate that macrophages and dendritic cells from NOD2-deficient mice were impaired in the production of proinflammatory cytokines and nitric oxide following infection with live, virulent M. tuberculosis. Mycolylarabinogalactan peptidoglycan (PGN), the cell wall core of M. tuberculosis, stimulated macrophages to release tumor necrosis factor (TNF) and interleukin-12p40 in a partially NOD2-dependent manner, and M. tuberculosis PGN required NOD2 for the optimal induction of TNF. However, NOD2-deficient mice were no more susceptible to infection with virulent M. tuberculosis than wild-type mice: they controlled the replication of M. tuberculosis in lung, spleen, and liver as well as wild-type mice, and both genotypes displayed similar lung pathologies. In addition, mice doubly deficient for NOD2 and TLR2 were similarly able to control an M. tuberculosis infection. Thus, NOD2 appears to participate in the recognition of M. tuberculosis by antigen-presenting cells in vitro yet is dispensable for the control of the pathogen during in vivo infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17709422      PMCID: PMC2168277          DOI: 10.1128/IAI.00458-07

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  41 in total

1.  Mycobacterial surface moieties are released from infected macrophages by a constitutive exocytic event.

Authors:  W L Beatty; H J Ullrich; D G Russell
Journal:  Eur J Cell Biol       Date:  2001-01       Impact factor: 4.492

2.  An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow.

Authors:  M B Lutz; N Kukutsch; A L Ogilvie; S Rössner; F Koch; N Romani; G Schuler
Journal:  J Immunol Methods       Date:  1999-02-01       Impact factor: 2.303

3.  Nucleotide binding oligomerization domain 2 deficiency leads to dysregulated TLR2 signaling and induction of antigen-specific colitis.

Authors:  Tomohiro Watanabe; Atsushi Kitani; Peter J Murray; Yoshio Wakatsuki; Ivan J Fuss; Warren Strober
Journal:  Immunity       Date:  2006-08-31       Impact factor: 31.745

4.  Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract.

Authors:  Koichi S Kobayashi; Mathias Chamaillard; Yasunori Ogura; Octavian Henegariu; Naohiro Inohara; Gabriel Nuñez; Richard A Flavell
Journal:  Science       Date:  2005-02-04       Impact factor: 47.728

5.  Role of nod2 in the response of macrophages to toll-like receptor agonists.

Authors:  Anne-Laure Pauleau; Peter J Murray
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

6.  Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with Blau syndrome.

Authors:  Nobuo Kanazawa; Ikuo Okafuji; Naotomo Kambe; Ryuta Nishikomori; Mami Nakata-Hizume; Sonoko Nagai; Akihiko Fuji; Takenosuke Yuasa; Akira Manki; Yoshihiko Sakurai; Mitsuru Nakajima; Hiroko Kobayashi; Ikuma Fujiwara; Hiroyuki Tsutsumi; Atsushi Utani; Chikako Nishigori; Toshio Heike; Tatsutoshi Nakahata; Yoshiki Miyachi
Journal:  Blood       Date:  2004-09-30       Impact factor: 22.113

7.  NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses.

Authors:  Tomohiro Watanabe; Atsushi Kitani; Peter J Murray; Warren Strober
Journal:  Nat Immunol       Date:  2004-06-27       Impact factor: 25.606

8.  Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease.

Authors:  Naohiro Inohara; Yasunori Ogura; Ana Fontalba; Olga Gutierrez; Fernando Pons; Javier Crespo; Koichi Fukase; Seiichi Inamura; Shoichi Kusumoto; Masahito Hashimoto; Simon J Foster; Anthony P Moran; Jose L Fernandez-Luna; Gabriel Nuñez
Journal:  J Biol Chem       Date:  2003-01-04       Impact factor: 5.157

9.  Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection.

Authors:  Stephen E Girardin; Ivo G Boneca; Jérôme Viala; Mathias Chamaillard; Agnès Labigne; Gilles Thomas; Dana J Philpott; Philippe J Sansonetti
Journal:  J Biol Chem       Date:  2003-01-13       Impact factor: 5.157

10.  NOD2 and toll-like receptors are nonredundant recognition systems of Mycobacterium tuberculosis.

Authors:  Gerben Ferwerda; Stephen E Girardin; Bart-Jan Kullberg; Lionel Le Bourhis; Dirk J de Jong; Dennis M L Langenberg; Reinout van Crevel; Gosse J Adema; Tom H M Ottenhoff; Jos W M Van der Meer; Mihai G Netea
Journal:  PLoS Pathog       Date:  2005-11-25       Impact factor: 6.823

View more
  42 in total

Review 1.  IL-17 and Th17 cells in tuberculosis.

Authors:  Egídio Torrado; Andrea M Cooper
Journal:  Cytokine Growth Factor Rev       Date:  2010-11-12       Impact factor: 7.638

Review 2.  Unleashing the therapeutic potential of NOD-like receptors.

Authors:  Kaoru Geddes; João G Magalhães; Stephen E Girardin
Journal:  Nat Rev Drug Discov       Date:  2009-06       Impact factor: 84.694

3.  NOD2 controls the nature of the inflammatory response and subsequent fate of Mycobacterium tuberculosis and M. bovis BCG in human macrophages.

Authors:  Michelle N Brooks; Murugesan V S Rajaram; Abul K Azad; Amal O Amer; Martin A Valdivia-Arenas; Jong-Hwan Park; Gabriel Núñez; Larry S Schlesinger
Journal:  Cell Microbiol       Date:  2010-11-24       Impact factor: 3.715

4.  Common polymorphisms in the NOD2 gene region are associated with leprosy and its reactive states.

Authors:  William Richard Berrington; Murdo Macdonald; Saraswoti Khadge; Bishwa Raj Sapkota; Marta Janer; Deanna Alisa Hagge; Gilla Kaplan; Thomas Richard Hawn
Journal:  J Infect Dis       Date:  2010-05-01       Impact factor: 5.226

Review 5.  T regulatory cells: Achilles' heel of Mycobacterium tuberculosis infection?

Authors:  Om Parkash; Sonali Agrawal; M Madhan Kumar
Journal:  Immunol Res       Date:  2015-07       Impact factor: 2.829

6.  Species-specific engagement of human nucleotide oligomerization domain 2 (NOD)2 and Toll-like receptor (TLR) signalling upon intracellular bacterial infection: role of Crohn's associated NOD2 gene variants.

Authors:  M Salem; J B Seidelin; S Eickhardt; M Alhede; G Rogler; O H Nielsen
Journal:  Clin Exp Immunol       Date:  2015-03       Impact factor: 4.330

Review 7.  Immunometabolism within the tuberculosis granuloma: amino acids, hypoxia, and cellular respiration.

Authors:  Joseph E Qualls; Peter J Murray
Journal:  Semin Immunopathol       Date:  2015-10-21       Impact factor: 9.623

8.  The adaptor molecule CARD9 is essential for tuberculosis control.

Authors:  Anca Dorhoi; Christiane Desel; Vladimir Yeremeev; Lydia Pradl; Volker Brinkmann; Hans-Joachim Mollenkopf; Karin Hanke; Olaf Gross; Jürgen Ruland; Stefan H E Kaufmann
Journal:  J Exp Med       Date:  2010-03-29       Impact factor: 14.307

9.  Increased NOD2-mediated recognition of N-glycolyl muramyl dipeptide.

Authors:  François Coulombe; Maziar Divangahi; Frédéric Veyrier; Louis de Léséleuc; James L Gleason; Yibin Yang; Michelle A Kelliher; Amit K Pandey; Christopher M Sassetti; Michael B Reed; Marcel A Behr
Journal:  J Exp Med       Date:  2009-07-06       Impact factor: 14.307

10.  The NOD/RIP2 pathway is essential for host defenses against Chlamydophila pneumoniae lung infection.

Authors:  Kenichi Shimada; Shuang Chen; Paul W Dempsey; Rosalinda Sorrentino; Randa Alsabeh; Anatoly V Slepenkin; Ellena Peterson; Terence M Doherty; David Underhill; Timothy R Crother; Moshe Arditi
Journal:  PLoS Pathog       Date:  2009-04-10       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.